[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D001565:Benzoates / Q000008:administration & dosage / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D048909:Diabetes Complications; D004359:Drug Therapy, Combination; D006801:Humans; D009203:Myocardial Infarction / Q000517:prevention & control*; D010919:Placebos; D017257:Ramipril / Q000008:administration & dosage / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D000077333:Telmisartan; D013997:Time Factors
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D010919:Placebos; D017257:Ramipril; D000077333:Telmisartan
Gefässpatient mit hohem Infarktrisiko. Schützt der AT1-Blocker so gut wie ein ACE-Hemmer?